Transgene Sa

Availability of Transgene’s 2025 Universal Registration Document (URD)

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

Transgene Announces Financial Calendar for 2026

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero